Staphylococcal Vaccines and Immunotherapies

Infectious Disease Clinics of North America

Volumn 23, Issue 1, 2009, Pages 153-171

  Schaffer, Adam C ^a   Lee, Jean C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Active immunization; Passive immunization; Staphylococcus aureus; Vaccine

Indexed keywords

ALPHA HEMOLYSIN; AUROGRAB; GLUCOSAMINE DERIVATIVE; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PAGIBAXIMAB; POLY N ACETYLGLUCOSAMINE; PSEUDOMONIC ACID; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; UNCLASSIFIED DRUG; VANCOMYCIN;

ACTIVE IMMUNIZATION; ATHLETE; BACTEREMIA; BACTERIAL VIRULENCE; CLINICAL TRIAL; DIABETIC PATIENT; DISEASE CARRIER; ELECTIVE SURGERY; FIRE FIGHTER; HEALTH CARE PERSONNEL; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPROMISED PATIENT; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INSTITUTIONAL CARE; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ABUSE; LOW BIRTH WEIGHT; MALE HOMOSEXUAL; NONHUMAN; NOSE MUCOSA; PASSIVE IMMUNIZATION; POLICE; PRISONER; QUORUM SENSING; REVIEW; SOLDIER; SPECIES COMPARISON; STAPHYLOCOCCUS INFECTION; SURGICAL PATIENT; THERAPY EFFECT; TREATMENT RESPONSE; VACCINE PRODUCTION;

EID: 58149316199     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2008.10.005     Document Type: Review

References (96)

1. Lowy F.D. Staphylococcus aureus infections. N Engl J Med 339 8 (1998) 520-532
2. Klein E., Smith D.L., and Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerging Infect Dis 13 12 (2007) 1840-1846
3. Chambers H.F. The changing epidemiology of Staphylococcus aureus?. Emerg Infect Dis 7 2 (2001) 178-182
4. Shastry L., Rahimian J., and Lascher S. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections in men who have sex with men in New York City. Arch Intern Med 167 8 (2007) 854-857
5. Daum R.S. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 357 4 (2007) 380-390
6. de Lencastre H., Oliveira D., and Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr Opin Microbiol 10 5 (2007) 428-435
7. Graber C.J., Wong M.K., Carleton H.A., et al. Intermediate vancomycin susceptibility in a community-associated MRSA clone. Emerg Infect Dis 13 3 (2007) 491-493
8. Chang S., Sievert D.M., Hageman J.C., et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 348 14 (2003) 1342-1347
9. Zhu W., Clark N.C., McDougal L.K., et al. Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan. Antimicrobial Agents Chemother 52 2 (2008) 452-457
10. Lee J.C. Staphylococcus aureus vaccine. In: Ellis R.W., and Brodeur B.R. (Eds). New bacterial vaccines (2003), Kluwer Academic/Plenum Publishers, New York 283-293
11. Deresinski S. Antistaphylococcal vaccines and immunoglobulins: current status and future prospects. Drugs 66 14 (2006) 1797-1806
12. Projan S.J., Nesin M., and Dunman P.M. Staphylococcal vaccines and immunotherapy: to dream the impossible dream?. Curr Opin Pharmacol 6 5 (2006) 473-479
13. Foster T.J. Immune evasion by staphylococci. Nat Rev Microbiol 3 12 (2005) 948-958
14. Yarwood J.M., Paquette K.M., Tikh I.B., et al. Generation of virulence factor variants in Staphylococcus aureus biofilms. J Bacteriol 189 22 (2007) 7961-7967
15. Gotz F. Staphylococcus and biofilms. Mol Microbiol 43 6 (2002) 1367-1378
16. Vaudaux P., Kelley W.L., and Lew D.P. Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat. Clin Infect Dis 43 8 (2006) 968-970
17. Sendi P., Rohrbach M., Graber P., et al. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis 43 8 (2006) 961-967
18. Minnaganti V.R., and Cunha B.A. Infections associated with uremia and dialysis. Infect Dis Clin North Am 15 2 (2001) 385-406
19. O'Riordan K., and Lee J.C. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 17 1 (2004) 218-234
20. Eskola J., Kayhty H., Takala A.K., et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 323 20 (1990) 1381-1387
21. Swingler G., Fransman D., and Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev 2 (2007) CD001729
22. Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med 355 14 (2006) 1466-1473
23. Maiden M.C.J., and Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359 9320 (2002) 1829-1831
24. Rennels M.B., Edwards K.M., Keyserling H.L., et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101 4 Pt 1 (1998) 604-611
25. Black S.B., Shinefield H.R., Ling S., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 9 (2002) 810-815
26. Fattom A., Schneerson R., Szu S.C., et al. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun 58 7 (1990) 2367-2374
27. Fattom A., Schneerson R., Watson D.C., et al. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun 61 3 (1993) 1023-1032
28. Fattom A.I., Sarwar J., Ortiz A., et al. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 64 5 (1996) 1659-1665
29. Lee J.C., Park J.S., Shepherd S.E., et al. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 65 10 (1997) 4146-4151
30. Shinefield H., Black S., Fattom A., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346 7 (2002) 491-496
31. Karakawa W.W., Sutton A., Schneerson R., et al. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 56 5 (1988) 1090-1095
32. Baddour L.M., Lowrance C., Albus A., et al. Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis. J Infect Dis 165 4 (1992) 749-753
33. Cocchiaro J.L., Gomez M.I., Risley A., et al. Molecular characterization of the capsule locus from nontypeable Staphylococcus aureus. Mol Microbiol 59 3 (2006) 948-960
34. Pohlmann-Dietze P., Ulrich M., Kiser K.B., et al. Adherence of Staphylococcus aureus to endothelial cells: influence of capsular polysaccharide, global regulator agr, and bacterial growth phase. Infect Immun 68 9 (2000) 4865-4871
35. Etz H., Minh D.B., Henics T., et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci U S A 99 10 (2002) 6573-6578
36. Torres V.J., Pishchany G., Humayun M., et al. Staphylococcus aureus IsdB is a hemoglobin receptor required for heme iron utilization. J Bacteriol 188 24 (2006) 8421-8429
37. Kuklin N.A., Clark D.J., Secore S., et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S aureus sepsis model. Infect Immun 74 4 (2006) 2215-2223
38. Foster T.J., and Hook M. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol 6 12 (1998) 484-488
39. Clarke S.R., and Foster S.J. Surface adhesins of Staphylococcus aureus. Adv Microb Physiol 51 (2006) 187-224
40. McDevitt D., Francois P., Vaudaux P., et al. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 11 2 (1994) 237-248
41. Vaudaux P.E., Francois P., Proctor R.A., et al. Use of adhesion-defective mutants of Staphylococcus aureus to define the role of specific plasma proteins in promoting bacterial adhesion to canine arteriovenous shunts. Infect Immun 63 2 (1995) 585-590
42. Moreillon P., Entenza J.M., Francioli P., et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 63 12 (1995) 4738-4743
43. Sullam P.M., Bayer A.S., Foss W.M., et al. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun 64 12 (1996) 4915-4921
44. Josefsson E., Hartford O., O'Brien L., et al. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184 12 (2001) 1572-1580
45. Vernachio J., Bayer A.S., Le T., et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 47 11 (2003) 3400-3406
46. Vernachio J.H., Bayer A.S., Ames B., et al. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 50 2 (2006) 511-518
47. Bloom B., Schelonka R., Kueser T., et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 24 10 (2005) 858-866
48. DeJonge M., Burchfield D., Bloom B., et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151 3 (2007) 260-265
49. Patti J.M. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22 Suppl 1 (2004) S39-S43
50. Weems Jr. J.J., Steinberg J.P., Filler S., et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50 8 (2006) 2751-2755
51. Hetherington S., Texter M., Wenzel E., et al. Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis. Antimicrob Agents Chemother 50 10 (2006) 3499-3500
52. Benjamin D.K., Schelonka R., White R., et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 26 5 (2006) 290-295
53. Rupp M.E., Holley Jr. H.P., Lutz J., et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51 12 (2007) 4249-4254
54. Garmory H.S., and Titball R.W. ATP-binding cassette transporters are targets for the development of antibacterial vaccines and therapies. Infect Immun 72 12 (2004) 6757-6763
55. Burnie J.P., Matthews R.C., Carter T., et al. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect Immun 68 6 (2000) 3200-3209
56. Ruhland G.J., and Fiedler F. Occurrence and structure of lipoteichoic acids in the genus Staphylococcus. Arch Microbiol 154 4 (1990) 375-379
57. von Aulock S., Morath S., Hareng L., et al. Lipoteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology 208 4 (2003) 413-422
58. Morath S., Geyer A., and Hartung T. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med 193 3 (2001) 393-397
59. Morath S., Stadelmaier A., Geyer A., et al. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J Exp Med 195 12 (2002) 1635-1640
60. Stoll B.J., Hansen N., Fanaroff A.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110 2 Pt 1 (2002) 285-291
61. Weisman L.E. Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. Arch Pediatr 14 Suppl 1 (2007) S31-S34
62. Maira-Litran T., Kropec A., Joyce J., et al. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide. Infect Immun 70 8 (2002) 4433-4440
63. Cramton S.E., Gerke C., Schnell N.F., et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun 67 10 (1999) 5427-5433
64. Kelly-Quintos C., Kropec A., Briggs S., et al. The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. J Infect Dis 192 11 (2005) 2012-2019
65. Maira-Litran T., Kropec A., Goldmann D.A., et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 73 10 (2005) 6752-6762
66. Cerca N., Jefferson K.K., Maira-Litran T., et al. Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. Infect Immun 75 7 (2007) 3406-3413
67. Stranger-Jones Y.K., Bae T., and Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103 45 (2006) 16942-16947
68. Mazmanian S.K., Skaar E.P., Gaspar A.H., et al. Passage of heme-iron across the envelope of Staphylococcus aureus. Science 299 5608 (2003) 906-909
69. Gyimesi E., Bankovich A.J., Schuman T.A., et al. Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunol Lett 95 2 (2004) 185-192
70. Mohamed N., Jones S.M., Casey L.S., et al. Heteropolymers: a novel technology against blood-borne infections. Curr Opin Mol Ther 7 2 (2005) 144-150
71. Lindorfer M.A., Hahn C.S., Foley P.L., et al. Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications. Immunol Rev 183 (2001) 10-24
72. Song L., Hobaugh M.R., Shustak C., et al. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 274 5294 (1996) 1859-1866
73. Liang X., Ji Y., Liang X., et al. Alpha-toxin interferes with integrin-mediated adhesion and internalization of Staphylococcus aureus by epithelial cells. Cell Microbiol 8 10 (2006) 1656-1668
74. Adlam C., Ward P.D., McCartney A.C., et al. Effect of immunization with highly purified alpha- and beta-toxins on staphylococcal mastitis in rabbits. Infect Immun 17 2 (1977) 250-256
75. Menzies B.E., and Kernodle D.S. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun 64 5 (1996) 1839-1841
76. Wardenburg J.B., and Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205 2 (2008) 287-294
77. Dinges M.M., Orwin P.M., and Schlievert P.M. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 13 1 (2000) 16-34
78. Murray R.J. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern Med J 35 Suppl 2 (2005) S106-S119
79. Lowell G.H., Colleton C., Frost D., et al. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect Immun 64 11 (1996) 4686-4693
80. LeClaire R.D., Hunt R.E., Bavari S., et al. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun 70 5 (2002) 2278-2281
81. George E.A., and Muir T.W. Molecular mechanisms of agr quorum sensing in virulent staphylococci. Chembiochem 8 8 (2007) 847-855
82. Goerke C., and Wolz C. Regulatory and genomic plasticity of Staphylococcus aureus during persistent colonization and infection. Int J Med Microbiol 294 2-3 (2004) 195-202
83. Park J., Jagasia R., Kaufmann G.F., et al. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 14 10 (2007) 1119-1127
84. Kluytmans J., van Belkum A., and Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 10 3 (1997) 505-520
85. Wertheim H.F.L., Melles D.C., Vos M.C., et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5 12 (2005) 751-762
86. Wertheim H.F., Vos M.C., Ott A., et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus noncarriers. Lancet 364 9435 (2004) 703-705
87. von Eiff C., Becker K., Machka K., et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 344 1 (2001) 11-16
88. Kluytmans J.A., and Wertheim H.F. Nasal carriage of Staphylococcus aureus and prevention of nosocomial infections. Infection 33 1 (2005) 3-8
89. Jones J.C., Rogers T.J., Brookmeyer P., et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 45 5 (2007) 541-547
90. Schaffer A.C., Solinga R.M., Cocchiaro J., et al. Immunization with Staphylococcus aureus clumping factor B, a major determinant in nasal carriage, reduces nasal colonization in a murine model. Infect Immun 74 4 (2006) 2145-2153
91. Clarke S.R., Brummell K.J., Horsburgh M.J., et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 193 8 (2006) 1098-1108
92. Welch P.G., Fattom A., Moore Jr. J., et al. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J Am Soc Nephrol 7 2 (1996) 247-253
93. Tanzi E., Amendola A., Pariani E., et al. Lack of effect of a booster dose of influenza vaccine in hemodialysis patients. J Med Virol 79 8 (2007) 1176-1179
94. Johnson D.W., and Fleming S.J. The use of vaccines in renal failure. Clin Pharmacokinet 22 6 (1992) 434-446
95. Watts A., Ke D., Wang Q., et al. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun 73 6 (2005) 3502-3511
96. Risley A.L., Loughman A., Cywes-Bentley C., et al. Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets. J Infect Dis 196 6 (2007) 919-927